Long-term follow-up of 90Y-ibritumomab-tiuxetan (90YIT) in the conditioning of autologous hematopoietic transplantation for indolent and mantle cell lymphomas in a single French center

DOI PubMed Open Access

Search this article

Description

High-dose therapy followed by autologous hematopoietic stem cell transplantation (ASCT) for refractory/relapsed indolent non-Hodgkin (iNHLs) and mantle cell lymphomas (MCLs) has shown significant improvement regarding PFS and overall survival (OS). iNHLs are also known to be highly radiosensitive diseases. Radio immunotherapy (RIT) approach such as 90Y-ibritumomab-tiuxetan (90YIT, Zevalin, Bayer Schering Pharma AG, Berlin, Germany) combined with high-dose chemotherapy protocols like BEAM (carmustine, etoposide, cytarabine and melphalan) were developed in an attempt to improve the antitumoral potency of the conditioning regimens. Since 2006, several studies have described promising results in relapsed or refractory NHLs with heterogeneous cohorts including iNHLs but also a majority of aggressive lymphomas.1, 2, 3, 4, 5 Only one phase II prospective study in indolent lymphomas showed a benefit of 90YIT in association with BEAM (Z-BEAM) as intensive therapy.6 There is a lack of data about the efficacy and safety of Z-BEAM conditioning regimen in iNHLs especially because of short follow-up in the published data. We report here the outcome from a cohort of high-risk iNHL treated with 90YIT added to BEAM regimen (Z-BEAM) for ASCT with sustained follow-up in a single French center.

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top